Elios Therapeutics, LLC
10 articles about Elios Therapeutics, LLC
-
Elios Therapeutics Announces the Appointment of Mark H.N. Corrigan, M.D. as Chairman of the Board of Directors
2/10/2022
Elios Therapeutics, a biopharmaceutical company developing innovative personalized therapeutic cancer vaccines, today announced the appointment of Mark H.N. Corrigan, M.D. as Chairman of the Board of Directors effective immediately.
-
Elios Therapeutics Strengthens Board of Directors with Appointment of Key Financial Executive Michael Caprio
9/29/2021
Elios Therapeutics, LLC, an immuno-oncology company focused on the development and commercialization of next-generation, immune-mediated technologies for the treatment of cancer, today announced the appointment of Michael Caprio, C.P.A., an accomplished business executive, to the Company's Board of Directors.
-
Elios Therapeutics Personalized Cancer Vaccine Demonstrates Long-Term Survival Benefit Among High-Risk Melanoma Patients in Phase IIb Final Analysis
8/5/2020
~ 96 Percent of High-Risk Melanoma Patients Were Alive Three Years After Completing the Vaccine Series Compared to 77 Percent of those Treated with Placebo ~~ 52 Percent of Patients Treated with the Vaccine Were Disease-Free at Three Years Compared to 27 Percent in the Placebo Arm ~~ New Analysis Reveals Optimized Vaccine Formulation Results in Improved Clinical Outcomes ~~ Treatment with Vaccine in Combination with Checkpoint Inhibitors Doubled Disease-Free Surviva
-
Elios Therapeutics Presents New Phase IIb Data for Personalized Cancer Vaccine in High-Risk Melanoma Patients at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
2/7/2020
- Vaccine Was Most Effective in Stage IV Melanoma; 73 Percent of Patients Who Completed the Primary Vaccine Series Were Disease-Free at 24 Months - - Results Reflect Synergistic Anti-Tumor Effect When Vaccine is Combined with Checkpoint Inhibitors -
-
Elios Therapeutics Presents Primary Analysis of Phase IIb Study Showing Personalized Cancer Vaccine Significantly Reduces Risk of Melanoma Recurrence in High-Risk Patients
11/21/2019
Elios Therapeutics, a biopharmaceutical company developing innovative personalized therapeutic cancer vaccines, today announced that the Company presented the primary analysis of the prospective, randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating its tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine, in patients with Stage III and IV resected melanoma.
-
Elios Therapeutics Announces Positive Top-Line Data from Phase IIb Study Evaluating TLPLDC, a Personalized Therapeutic Cancer Vaccine, in Patients with High-Risk Melanoma
7/17/2019
Elios Therapeutics, today announced positive top-line results from the Company's prospective, randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating its lead immuno-oncology candidate, the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine, in patients with Stage III and IV resected melanoma.
-
Biotech and pharma companies tap new members of executive leadership teams and boards.
-
Elios Therapeutics Announces Appointment of Phillip Johnson as Chief Financial Officer
6/26/2019
Elios Therapeutics, a biopharmaceutical company developing innovative autologous, particle-delivered, dendritic cell cancer vaccines, announced the appointment of Phillip Johnson as chief financial officer, effective immediately.
-
Elios Therapeutics Announces Interim Phase IIb Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine for the Treatment of Melanoma, at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
6/1/2018
Interim Phase IIb Data Show Promising Reduction In Risk of Recurrence and a Well-Tolerated Safety Profile in Patients with Resected, High-Risk Melanoma
-
Elios Therapeutics, LLC Release: Novel Cancer Vaccine In Combination With Check Point Blockades Holds Promise
2/5/2016